RWE roundup – December 2018

002 FINAL SVMPharma RWE highlight infographic 03-01-2019


FDA releases new strategic framework for assessing the potential use of RWE in connection with drug review program

Click here to find out more



Researchers identify nutation in BCL2 protein that causes resistance to venetoclax in progressive CLL

Click here to find out more



NICE recommends MSD’s Keytruda within the CDF for stage III melanoma patients

Click here to find out more


About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit and contact us at

Posted in Blogs.